Log In Sign up
The largest database of trusted experimental protocols

Neratinib

Manufactured by Santa Cruz Biotechnology
Visit Supplier

Neratinib is a small molecule inhibitor that targets the tyrosine kinase activity of the HER2 and EGFR proteins. It is used in research applications to study the role of HER2 and EGFR signaling in various cellular processes.

Automatically generated - may contain errors

Lab products found in correlation

Lapatinib, by Santa Cruz Biotechnology (3 mentions) Erlotinib, by Santa Cruz Biotechnology (2 mentions) Dacomitinib, by Cayman Chemical (2 mentions) Afatinib, by Santa Cruz Biotechnology (2 mentions) Poziotinib, by Selleck Chemicals (1 mentions) Ibrutinib, by Selleck Chemicals (1 mentions) Prism 9, by GraphPad (1 mentions) Afatinib, by Boehringer Ingelheim (1 mentions) Gefitinib, by Santa Cruz Biotechnology (1 mentions) Osimertinib, by Cayman Chemical (1 mentions)

3 protocols using neratinib

1

Cytotoxicity Assays Investigating ERBB4 Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
Ba/F3 cells (20,000 cells/well) expressing ERBB4 variants were plated on 96-well plates in RPMI1640 medium containing 10 ng/mL NRG-1. Vector control cells were plated in RPMI1640 medium containing 5% WEHI conditioned medium. The cells were incubated in the presence or absence of 0.0005–10 µmol/L erlotinib (Santa Cruz Biotechnology), afatinib (Boehringer Ingelheim), neratinib (SantaCruz Biotechnology), dacomitinib (Cayman Chemicals), poziotinib (Selleck Chemicals), ibrutinib (Selleck Chemicals), or lapatinib (Santa Cruz Biotechnology), for 72 hours before measuring the viability of cells with MTT assay (described above). Sigmoidal dose–response curves were fitted using asymmetric five-parameter non-linear regression in GraphPad Prism 9 and are graphically displayed with GraphPad Prism 9. The IC50 values are calculated with the help of the R package “drc” (34 (link)) by using quadruplicate measurements from the MTT assay for the indicated concentrations from 3–5 individual experiments and fitting four-parametric log-logistic models (LL.4, LL2.4; R). The unpaired t test (Welch two-sample t test) was used to compare IC50 values.
Chakroborty D., Ojala V.K., Knittle A.M., Drexler J., Tamirat M.Z., Ruzicka R., Bosch K., Woertl J., Schmittner S., Elo L.L., Johnson M.S., Kurppa K.J., Solca F, & Elenius K. (2022). An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 Mutations. Cancer Research Communications, 2(1), 10-27.
+ Open protocol
+ Expand
2

Inhibition of ErbB Kinase Activity in Embryos

Check if the same lab product or an alternative is used in the 5 most similar protocols
To block ErbB kinase activity in the embryos, 10 µM of tyrosine kinase inhibitors AG 1478 (Calbiochem), erlotinib, gefitinib, lapatinib, afatinib, neratinib, canertinib (all from Santa-Cruz Biotechnologies), osimertinib, and dacomitinib (both from Cayman Chemical), diluted in DMSO, or DMSO alone was applied in E3 medium at 8 hpf, except as indicated for experimentation shown in Figure 4D. The final concentration of DMSO was 0.1% of the culture medium.
Paatero I., Veikkolainen V., Mäenpää M., Schmelzer E., Belting H.G., Pelliniemi L.J, & Elenius K. (2019). ErbB4 tyrosine kinase inhibition impairs neuromuscular development in zebrafish embryos. Molecular Biology of the Cell, 30(2), 209-218.
+ Open protocol
+ Expand
3

ERBB TKI Sensitivity in Ba/F3 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Quadruplicate aliquots of Ba/F3 cells (cultured in the presence or absence of IL3 and/or ERBB ligand as indicated) were seeded at 5,000 cells/96-well plate wells in a volume of 75 mL/well and incubated overnight. The following day ERBB TKIs erlotinib, lapatinib, afatinib, or neratinib (all from Santa Cruz Biotechnology) were applied in a volume of 75 mL/well to reach a final concentration ranging from 0 to 10 mmol/L. Cells were incubated in the presence of the drugs for another 72 hours, after which the number of viable cells was analyzed with the MTT-assays. Ba/F3 cells infected with an empty vector cells growing in the presence of IL3 served as a negative control.
Koivu M.K.A., Chakroborty D., Tamirat M.Z., Johnson M.S., Kurppa K.J, & Elenius K. (2021). Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line Databases. Molecular cancer therapeutics, 20(3).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!